Leerink Partnrs Has Pessimistic View of WVE FY2025 Earnings

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at Leerink Partnrs reduced their FY2025 earnings estimates for shares of WAVE Life Sciences in a research report issued on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.20) for the year, down from their previous estimate of ($1.15). The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for WAVE Life Sciences’ Q4 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($0.32) EPS.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). The company had revenue of $7.61 million for the quarter, compared to the consensus estimate of $9.85 million.

Several other brokerages have also issued reports on WVE. Citigroup initiated coverage on shares of WAVE Life Sciences in a research note on Wednesday, July 16th. They issued a “buy” rating and a $16.00 price target for the company. Leerink Partners set a $26.00 price target on WAVE Life Sciences in a research note on Wednesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $12.00 target price on shares of WAVE Life Sciences in a report on Monday, October 27th. Canaccord Genuity Group began coverage on shares of WAVE Life Sciences in a research note on Monday, August 4th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, B. Riley reaffirmed a “buy” rating on shares of WAVE Life Sciences in a report on Thursday, September 4th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.73.

WAVE Life Sciences Stock Down 4.3%

NASDAQ WVE opened at $6.95 on Thursday. The stock’s 50 day moving average is $7.46 and its 200 day moving average is $7.56. The firm has a market capitalization of $1.11 billion, a PE ratio of -7.72 and a beta of -1.44. WAVE Life Sciences has a twelve month low of $5.28 and a twelve month high of $16.71.

Insider Activity at WAVE Life Sciences

In related news, Director Gregory L. Verdine sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $10.00, for a total transaction of $100,000.00. Following the transaction, the director owned 285,217 shares in the company, valued at $2,852,170. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul Bolno sold 217,351 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $10.10, for a total transaction of $2,195,245.10. Following the completion of the sale, the chief executive officer owned 121,000 shares in the company, valued at $1,222,100. This represents a 64.24% decrease in their position. The SEC filing for this sale provides additional information. 23.98% of the stock is owned by insiders.

Institutional Trading of WAVE Life Sciences

Hedge funds have recently bought and sold shares of the company. Invesco Ltd. boosted its position in WAVE Life Sciences by 97.2% in the first quarter. Invesco Ltd. now owns 78,880 shares of the company’s stock worth $637,000 after purchasing an additional 38,870 shares during the last quarter. Strs Ohio purchased a new stake in shares of WAVE Life Sciences during the 1st quarter valued at about $406,000. Principal Financial Group Inc. lifted its stake in shares of WAVE Life Sciences by 23.9% in the 1st quarter. Principal Financial Group Inc. now owns 308,044 shares of the company’s stock worth $2,489,000 after purchasing an additional 59,399 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of WAVE Life Sciences by 16.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,974 shares of the company’s stock worth $339,000 after buying an additional 6,015 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of WAVE Life Sciences by 38.0% in the first quarter. New York State Common Retirement Fund now owns 150,513 shares of the company’s stock worth $1,216,000 after buying an additional 41,429 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.